Reported results
- Total revenues were $3.75 billion, with U.S. GAAP net loss of $325.3 million and U.S. GAAP diluted loss per share of $(0.28).
- Adjusted EBITDA was $1.20 billion, representing a 4% increase on a reported basis compared to the third quarter of 2025.
- Adjusted net earnings were $821.4 million, with adjusted EPS of $0.71 per share.
- U.S. GAAP net cash provided by operating activities was $899.4 million for the third quarter of 2026.
- Free cash flow was $813.7 million for the third quarter of 2026.
Guidance
- Total Revenues: $14,700 million - $14,900 million
- Adjusted EBITDA: $4,450 million - $4,550 million
- Adjusted EPS: $2.56 - $2.63
- Free Cash Flow (excluding transaction-related and restructuring-related costs): $2,225 million - $2,375 million
- U.S. GAAP net cash provided by operating activities: $2,025 million - $2,100 million
Notes
The third quarter 2026 U.S. GAAP net loss was primarily driven by an increase in income tax provision. The company announced a planned acquisition of Pacira BioSciences expected to close by the end of November 2026. Guidance excludes any contribution from the planned acquisition of Pacira BioSciences and acquired IPR&D for unsigned deals.
Price and volatility reaction
The stock moved -1.3% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -9.4 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 19.22 | 2026-11-04 |
| Close after release | 18.97 | 2026-11-05 |
| Realised move | -1.3% | close to close |
| 30d ATM IV change | -9.4 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.
